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ly 13, 2013.he purpose of this paper was to assess whether statins reduce all-cause mortality and cardiovascular (CV) events in
elderly people without established CV disease.Background Because of population aging, prevention of CV disease in the elderly is relevant. In elderly patients with previous CV
events, the use of statins is recommended by guidelines, whereas the beneﬁts of these drugs in elderly subjects
without previous CV events are still debated.Methods Randomized trials comparing statins versus placebo and reporting all-cause and CV mortality, myocardial infarction
(MI), stroke, and new cancer onset in elderly subjects (age65 years) without established CV disease were included.Results Eight trials enrolling 24,674 subjects (42.7% females; mean age 73.0  2.9 years; mean follow up 3.5  1.5 years)
were included in analyses. Statins, compared with placebo, signiﬁcantly reduced the risk of MI by 39.4% (relative
risk [RR]: 0.606 [95% conﬁdence interval (CI): 0.434 to 0.847]; p ¼ 0.003) and the risk of stroke by 23.8% (RR:
0.762 [95% CI: 0.626 to 0.926]; p ¼ 0.006). In contrast, the risk of all-cause death (RR: 0.941 [95% CI: 0.856 to
1.035]; p ¼ 0.210) and of CV death (RR: 0.907 [95% CI: 0.686 to 1.199]; p ¼ 0.493) were not signiﬁcantly reduced.
New cancer onset did not differ between statin- and placebo-treated subjects (RR: 0.989 [95% CI: 0.851 to 1.151];
p ¼ 0.890).Conclusions In elderly subjects at high CV risk without established CV disease, statins signiﬁcantly reduce the incidence of MI and
stroke, but do not signiﬁcantly prolong survival in the short-term. (J Am Coll Cardiol 2013;62:2090–9) ª 2013 by
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deaths in individuals older than age 65 years who are more
frequently affected by comorbidities, including diabetes
mellitus, hypertension, hyperlipidemia, and renal dysfunc-
tion, compared with younger people (1). Because of pop-
ulation aging, prevention of CV disease in the elderly
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3; revised manuscript received July 3, 2013,The beneﬁt of hydroxyl methyl glutaryl coenzyme A
reductase inhibitors (statins) is established in patients with
previous CV events (2), and intensive low-density lipo-
protein (LDL) cholesterol lowering is recommended by
guidelines (3,4). In addition, evidence indicates that statins
substantially reduce CV events and all-cause mortality in
patients without previous CV events (5) or at low CV risk
(6). In elderly patients (age 65 years) with previous CVSee page 2100events, the use of statins is recommended by guidelines (3,4)
based on evidence from 1 clinical trial enrolling elderly
patients with and without CV disease (7) and 1 meta-analysis
(8). In contrast, in elderly patients without CV events, the
use of statins is not advocated by guidelines (Level of
Recommendation: IIb in European Society of Cardiology
guidelines [3]) because no clinical trials have assessed the
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2091risk-beneﬁt of statin use in this age group and only subgroup
analyses from randomized studies are available (5).
Thus, we designed ameta-analysis to assess whether statins
reduce all-cause mortality and CV events in elderly people
without established CV disease.LDL = low-density lipoprotein
MI = myocardial infarction
RR = relative risk
Methods
Search strategy. The study was designed according to the
PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) statement (9). MEDLINE,
Cochrane, ISI Web of Science, and SCOPUS databases
were searched for articles published until January 2013
combining the following medical subject heading terms:
“hydroxymethylglutaryl-CoA reductase inhibitors” and
(“aged” or “aged, 80 and over”) and “randomized controlled
trial” and the following search terms (“pravastatin” or
“lovastatin” or “simvastatin” or “rosuvastatin” or “atorvasta-
tin” or “pitavastatin” or “mevastatin” or “ﬂuvastatin” or
“statin”) and “randomized controlled trial.” No language
restrictions were applied.
Study selection. Study inclusion criteria were: randomized
allocation to statin or placebo; report of outcomes in the
subgroup of patients with age at randomization 65 years
and without established CV disease; and report of at least
1 clinical event among all-cause death, CV death, myocar-
dial infarction (MI), stroke, and new cancer onset.
Data extraction and quality assessment. Papers identiﬁed
in the literature search were screened by 2 independent
reviewers (G.S., S.P.) to assess their eligibility for the
analysis. Discrepancies were resolved by the senior author
(P.P.F.). Corresponding authors were asked to provide full-
text papers, if they were not available. From each study,
information about methods, year of publication, number of
patients in treatment and control arms, duration of follow-
up, age, sex, CV risk factors, medications, baseline and
change in lipid levels, and treatment drug and dose were
collected and entered into STATA (version 12.0, Stata-
Corp., College Station, Texas) by 1 author (G.S.) and
checked by the senior author (P.P.F.). The pre-speciﬁed
outcomes abstracted from selected trials were all-cause
death, CV death, MI, stroke, and new cancer onset.
When a potentially eligible trial that lacked essential infor-
mation (outcomes) was identiﬁed, the corresponding author
was asked to complete a form that included the required
information. The GRADE (Grading of Recommendations
Assessment, Development and Evaluation) method was
used to summarize the ﬁndings and score the overall quality
of evidence (10).
Data synthesis and analysis. Relative risks (RRs) of the
effect of randomized treatments were calculated using
the “metan” routine (STATA version 12.0, Statacorp,
College Station, Texas) to account for the probability of
events occurring in the treatment group versus the placebo
group (11). The RR and 95% conﬁdence interval (CI) for
each outcome were separately calculated for each trialwith grouped data, using the
intention-to-treat principle (12).
Pooled RRs were logarithmically
transformed and weighted for
the inverse of variance. Overall
estimates of effect were calcu-
lated with a ﬁxed-effects model
or with a random-effects model
when heterogeneity could not be
explained (13). The assumption of homogeneity between
the treatment effects in different trials was tested by Q
statistic and further quantiﬁed by I2 statistic. The signiﬁ-
cance level for the overall estimates of effect was set at
p  0.05, whereas it was set at p  0.10 for the presence of
heterogeneity and publication bias. The objective of the
study was to investigate the effects of statin therapy on all-
cause death, CV death, MI, stroke, and new cancer onset
in elderly patients without established CV disease.
Sensitivity analysis. To verify the consistency of outcome
meta-analysis results, the inﬂuence of each individual study
on the summary effect estimate was assessed by the 1-study
removed sensitivity analysis using the “metaninf” command
(STATA) (14). To explore the inﬂuence of potential effect
modiﬁers on outcomes, weighted random-effects meta-
regression analysis was performed with the “metareg” com-
mand (STATA) to test demographic characteristics of the
study population, duration of follow-up, CV risk factors
(including diabetes mellitus and hypertension), type of sta-
tin, concomitant medications, and changes in lipid proﬁle
from baseline to the end of follow-up (15,16). For all meta-
regression analyses, the weight used for each trial was the
inverse of the sum of the within-trial variance and the
residual between trial variance. Additionally, the residual
maximum likelihood methods were employed to explain
residual heterogeneity not explained by potential effect
modiﬁers, including an additive between-study variance
component Tau2 (16,17).
Publication bias. To evaluate potential publication bias,
a weighted linear regression was used with the natural log of
the odds ratio as the dependent variable and the inverse of
the total sample size as the independent variable. This is
a modiﬁed Macaskill’s test, which gives more balanced type I
error rates in the tail probability areas in comparison with
other publication bias tests (16,18).Results
Characteristics of included trials. The characteristics of
included trials are outlined in Table 1. Of 24,405 papers
identiﬁed in the initial search, 46 were retrieved for more
detailed evaluation. Thirty-eight studies were subsequently
excluded: 25 trials enrolled patients with established CV
disease; 7 trials reported duplicate data; 2 trials reported
no clinical endpoint (19,20); 1 trial excluded patients
age >70 years, leaving too few elderly patients to be included
in analyses (21); 1 large (22) and 2 small (23,24) randomized
Table 1 Baseline Characteristics of Trials Included in Analyses
Trial (Ref. #) Year
Patients
(n) Treatment
Follow-Up
(yrs) Age (yrs)
Baseline TC
(mmol/l)
DTC
(%)
Baseline LDL-C
(mmol/l)
DLDL-C
(%)
Baseline HDL-C
(mmol/l)
DHDL-C
(%)
AFCAPS/TexCAPS (25) 1998 1,416 Lovastatin 20/40 mg 5.2 NA 5.70 6.80 4.06 13.90 0.99 2.56
ALLHAT-LLT (26) 2002 5,707 Pravastatin 40 mg 4.8 NA 5.79* 16.32* 3.77* 22.69* 1.23* 1.62*
ASCOT-LLA (30) 2011 4,445 Atorvastatin 10 mg 3.3 71 5.48* 13.91* 3.44* 18.54* 1.31* 0.77*
Bruckert et al. (27) 2002 1,229 Fluvastatin 80 mg 1 75 7.28 13.69 5.18 17.89 1.36 0
CARDS (28) 2006 1,129 Atorvastatin 10 mg 3.9 69 5.36* 12.38* 3.03* 13.92* 1.40* 11.36*
JUPITER (29) 2010 5,695 Rosuvastatin 20 mg 1.9 74 4.82* NA 2.80 25.27 1.27* 1.57*
MEGA (31) 2011 1,814 Pravastatin 10/20 mg 5 NA 6.27* 7.32* 4.05* 11.95* 1.49* 6.02*
PROSPER (7) 2002 3,239 Pravastatin 40 mg 3.2 75* 5.70y NA 3.80þ 22.79y 1.30y NA
Baseline TG
(mmol/l)
DTG
(%) Age (yrs)
Females
(%)
HTN
(%)
DM
(%)
Smoking
(%) Inclusion Criteria
AFCAPS/TexCAPS (25) 1.96 7.18 NA 25 NA 6* 12* Patients with average cholesterol levels and without prior CV disease
ALLHAT-LLT (26) 1.71* 6.41* NA 49* 100 NA NA Moderate hypercholesterolemia, HTN
ASCOT-LLA (30) 1.65* 15.92* 71 20 100 27 24 HTN and at least 3 CV risk factors
Bruckert (27) 1.53 6.12 76 75 56 7 5 Primary hypercholesterolemia
CARDS (28) 1.94* 9.64* 69 31 NA 100 16 Type 2 DM and at least 1 other CV risk factor
JUPITER (29) 1.33* 7.98* 74 51 66 NA 8 CRP >2.0 mg/l
MEGA (31) 1.44* 11.42* NA 68* 52 21 14 Hypercholesterolemic Japanese patients
PROSPER (7) 1.50y NA 75y 52y 62y 11y 27y Raised risk of CV disease because of smoking, HTN, or DM
To convert total cholesterol, LDL-C, and HDL-C from mmol/l to mg/dl, divide by 0.0259. To convert triglycerides from mmol/l to mg/dl, divide by 0.0113. *Data from the published cohort of young and elderly patients. yData from the published cohort of primary and secondary
prevention patients.
AFCAPS/TexCAPS ¼ Air Force/Texas Coronary Atherosclerosis Prevention Study; ALLHAT-LLT ¼ Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ASCOT-LLA ¼ Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm; BB ¼ beta-blocker;
CARDS ¼ Collaborative Atorvastatin Diabetes Study; CRP ¼ C-reactive protein; CV ¼ cardiovascular; DM ¼ diabetes mellitus; HDL-C ¼ high-density lipoprotein cholesterol; HTN ¼ hypertension; JUPITER ¼ Justiﬁcation for the Use of statins in Prevention: an Intervention Trial
Evaluating Rosuvastatin; LDL-C ¼ low-density lipoprotein cholesterol; MEGA ¼ Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese; MI ¼ myocardial infarction; NA ¼ not available; PROSPER ¼ Prospective Study of Pravastatin in the Elderly
at Risk; TC ¼ total cholesterol; TG ¼ triglycerides.
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2093clinical studies having missing information that we could not
obtain from the authors. Therefore, 8 trials (7,25–31) were
ﬁnally included in the analyses, which enrolled 24,674
patients (42.7% females; mean age 73.0  2.9 years; mean
follow-up 3.5  1.5 years), 12,292 of which were assigned to
statin treatment and 12,382 to the placebo (Fig. 1).
Methodological quality. All studies included in analyses
were randomized, high-quality trials without major me-
thodological limitations (Table 2). In particular, no incon-
sistency of results, publication bias, or imprecision among
studies were identiﬁed according to the SCORE grading
method. Nonsigniﬁcant limitations were identiﬁed for 8 trials,
7 of which had double-blinded study design (7,25–30) and 1
was an open-label study (31).
Effects of statins on lipid proﬁle. In statin-treated
patients, baseline mean total cholesterol was 6.01  0.70
mmol/l and decreased by 1.22  0.31 mmol/l (20%) at
the end of follow-up, whereas in placebo-treated patients,
total cholesterol was 6.02  0.70 mmol/l at baseline
and decreased by 0.26  0.24 mmol/l (4%) at the end of
follow-up. In statin-treated patients, LDL cholesterol
was 3.76  0.73 mmol/l at baseline and decreased
by 1.16  0.26 mmol/l (31%) at the end of follow-up,Figure 1 Meta-Analysis Flow Chartwhereas in placebo-treated patients, LDL cholesterol
was 3.77  0.74 mmol/l at baseline and decreased by
0.21  0.24 mmol/l (6%) at the end of follow-up. In statin-
treated patients, high-density lipoprotein cholesterol level
was 1.29  0.16 mmol/l at baseline and increased by
0.01  0.07 mmol/l (1%) at the end of follow-up, whereas
in placebo-treated patients, high-density lipoprotein
cholesterol level was 1.29  0.16 mmol/l at baseline
and decreased by 0.02  0.08 mmol/l (2%) at the end of
follow-up. In statin-treated patients, triglycerides level
was 1.66  0.23 mmol/l at baseline and decreased by
0.24  0.09 mmol/l (14%) at the end of follow-up,
whereas in placebo-treated patients, triglycerides level
was 1.64  0.26 mmol/l at baseline and decreased by
0.06  0.07 mmol/l (4%) at the end of follow-up.
Outcome analysis. MI occurred in 2.7% of subjects allo-
cated to statins compared with 3.9% of those in placebo
during a mean follow-up of 3.5 years. Thus, statins signif-
icantly reduced the risk of MI by 39.4% compared with
placebo (RR: 0.606 [95% CI: 0.434 to 0.847]; comparison
p ¼ 0.003; heterogeneity p ¼ 0.028; random effects model)
(Fig. 2). Annual MI rate was 1.1% in patients allocated to
placebo, and 24 patients needed to be treated for 1 year to
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2094prevent 1 event. Stroke was reported in 2.1% of subjects
randomized to statins compared with 2.8% in placebo
during a mean follow-up of 3.5 years. Thus, statins signif-
icantly reduced the risk of stroke by 23.8% compared with
placebo (RR: 0.762 [95% CI: 0.626 to 0.926]; comparison
p ¼ 0.006; heterogeneity p ¼ 0.130; ﬁxed effects model)
(Fig. 2). Annual rate of stroke was 0.8% in patients
randomized to placebo, and 42 patients needed to be treated
for 1 year to prevent 1 event.
Statins did not signiﬁcantly reduce the risk of all-cause
death compared with placebo (RR: 0.941 [95% CI: 0.856
to 1.035]; comparison p ¼ 0.210; heterogeneity p ¼ 0.570;
ﬁxed effects model) (Fig. 3) and the risk of CV death (RR:
0.907 [95% CI: 0.686 to 1.199]; comparison p ¼ 0.493;
heterogeneity p ¼ 0.831; ﬁxed effects model) (Fig. 3).
New cancer onset was reported in 5.4% of subjects in both
treatment and placebo groups, with no signiﬁcant difference
of risk (RR: 0.989 [95% CI: 0.851 to 1.151]; comparison
p ¼ 0.890; heterogeneity p ¼ 0.492; ﬁxed effects model)
(Fig. 4).
Sensitivity analysis. Results were conﬁrmed when the
meta-analysis was repeated removing 1 study at the time.
Signiﬁcant heterogeneity affecting analysis for MI was
resolved by excluding the PROSPER trial, and the results
were conﬁrmed (RR: 0.542 [95% CI: 0.421 to 0.698];
comparison p ¼ 0.001; heterogeneity p ¼ 0.505).
By meta-regression analysis, no potential effect modiﬁers
(including sex, diabetic status, and hypertension) inﬂuenced
the ﬁndings of the meta-analysis.
Publication bias. No publication bias was found for each
outcome considered in the analyses.
Discussion
The ﬁndings of this meta-analysis indicate that statins
reduce the risk of MI and stroke in elderly subjects without
established CV disease in a short-term follow-up, with a
nonsigniﬁcant favorable trend toward reduction of mortality.
Primary CV prevention in the elderly. Due to aging of the
population, a large and increasing number of CV events
(more than two-thirds) occur in elderly (age 65 years)
subjects (4). In addition, due to the higher number of elderly
individuals without established CV disease, the majority of
CV events occur in these patients, despite the relative lower
risk for individuals without previous CV disease when
compared with individuals with previous CV events (32).
Recent guidelines have broadened the indication for statin
treatment and intensive cholesterol lowering to include
subjects without coronary artery disease affected by comor-
bidities, including diabetes mellitus, peripheral arterial
diseases, or renal dysfunction, which portend a very high CV
risk (3). As these conditions are more common in elderly
compared with younger individuals, there is a need to
ascertain whether statin treatment should be advocated in
elderly people without established CV disease but at high or
very high CV risk.
Figure 2 RRs of Myocardial Infarction and Stroke
Gray squares represent relative risks (RRs) in trials. The 95% conﬁdence intervals (CIs) for individual trials are denoted by lines and those for the pooled RRs by open diamonds.
Meta-analysis is performed by ﬁxed effects model. AFCAPS/TexCAPS ¼ Air Force/Texas Coronary Atherosclerosis Prevention Study; ALLHAT-LLT ¼ Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial; ASCOT-LLA ¼ Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm; CARDS ¼ Collaborative Atorvastatin Diabetes
Study; JUPITER ¼ Justiﬁcation for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; MEGA ¼ Management of Elevated Cholesterol in the Primary
Prevention Group of Adult Japanese; PROSPER ¼ Prospective Study of Pravastatin in the Elderly at Risk.
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2095Yet, there is currently no deﬁnitive indication for statin
treatment in elderly subjects with risk factors but without
established CV disease. Recent European Society of
Cardiology guidelines (3) assign statin treatment in this
population Class IIb and Level of Evidence: B due to lack of
clinical studies or meta-analysis. The Adult Treatment
Panel III (4), instead, advises that treatment in elderly people
should be driven by Framingham risk score calculation,
although absolute CV risk calculation from the risk chart
is not recommended in people older than age 80 years (4).
Previous studies. Despite a lack of clinical trials of primary
prevention in the elderly, no meta-analysis has been con-
ducted thus far. In fact, the only available information on the
effects of statins in elderly individuals without CV disease
comes from the meta-analysis of Brugts et al. (5), which
reported the effects of statins in subjects without CV disease.
At variance with the current analysis, this previous study
was not focused on the elderly population, although in
a subgroup analysis, authors reported no heterogeneity of the
effects of statins on outcomes between patients older or
younger than age 65 years. However, all CIs for outcomes in
the subgroup of patients 65 years of age crossed theidentity line, indicating no deﬁnitive evidence of beneﬁt.
Notably, the study did not report a separate analysis of
stroke and MI risk in elderly people. Thus, these previous
data did not allow a meaningful assessment of the beneﬁt
of statins in primary prevention in elderly individuals.
Current study. The current meta-analysis provides ﬁrst-
time evidence that the beneﬁts of statins on major CV
events extend to people 65 years without CV disease.
These ﬁndings are consistent with the favorable effect
of statins reported in subjects without CV disease in 2
previous meta-analyses (8,33). In fact, Mills et al. (34),
in a meta-analysis on the effects of statins in primary
prevention, reported a 23% reduction of MI and a 12%
reduction of stroke by statin treatment, whereas more
recently, Taylor et al. (33) reported a 27% reduction of fatal
and nonfatal coronary events and a 22% reduction of stroke
in subjects without CV events treated with statins. In their
meta-analysis, Mills et al. (34) also reported a signiﬁcant
effect of statins on total mortality (7% risk reduction) and
CV mortality (11%), whereas Taylor et al. (33) reported
a signiﬁcant 14% reduction of all-cause mortality in statin-
treated subjects. These previous observations are consistent
Figure 3 RRs of All-Cause Death and Cardiovascular Death
Gray squares represent RRs in trials. The 95% CIs for individual trials are denoted by lines and those for the pooled RRs by open diamonds. Meta-analysis is performed by ﬁxed
effects model. Abbreviations as in Figure 2.
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2096with the 6% nonsigniﬁcant total mortality reduction and the
9% nonsigniﬁcant CV mortality reduction observed in our
analysis.
In our study, a 39.4%MI risk reduction and a 23.8% stroke
risk reduction over 3.5 years of follow-up were observed
for a mean LDL cholesterol reduction of 0.69 mmol/l
(difference of changes from baseline to the end of study LDL
cholesterol values between treated and placebo patients for
each trial). Thus, a 57.1% MI risk reduction and a 34.5%
stroke reduction can be extrapolated for 1 mmol/l of LDL
cholesterol reduction in elderly people without known CV
disease, and this can be compared to the 29% MI risk and
15% stroke risk reduction per 1 mmol/l of LDL cholesterol
reduction reported by the Cholesterol Treatment Trialists’
Collaborators in their last meta-analysis in the general
population of patients enrolled in randomized clinical trials
(35). Our ﬁndings are also consistent with the 24% risk
reduction of major CV events in people without vascular
disease treated with statins, observed at all levels of CV risk
and conﬁrmed after stratiﬁcation for age and sex, that was
recently reported by the Cholesterol Treatment Trialists’
Collaborators (35). In particular, a 63% reduction of major
CV events was observed in elderly subjects (age >70 years)(35), showing a yearly event rate comparable to that observed
in the current study. In the population of patients collected
in our analysis, the annual event rate in placebo-treated
subjects was 0.5% for CV death, 1.1% for MI, and 0.8%
for stroke. According to recent guidelines (3), these event
rates correspond to a high-risk category of patients in whom
an LDL cholesterol target <100 mg/dl is recommended and
in whom drug (statin) treatment should be started if
cholesterol values are above target. Noteworthy, the on-
treatment mean LDL cholesterol of trials included in this
meta-analysis remained above the recommended target of
100 mg/dl, suggesting that a higher beneﬁt could be ach-
ieved in this population if the current recommend targets are
reached. Thus, the ﬁndings of the present meta-analysis
provide evidence for treatment of subjects at high CV risk
and older than age 65 years, and this may be relevant for
upgrading the level of recommendation for treatment in this
age group in future guidelines.
However, identiﬁcation of high-risk elderly patients
without established CV disease remains challenging, as
risk charts’ calculation of absolute CV risk over a 10-year
period does not apply to subjects older than age 80 years
(4). In the present analysis, elderly subjects in primary
Figure 4 RRs of New Cancer Onset
Gray squares represent RRs in trials. The 95% CIs for individual trials are denoted by lines and those for the pooled RRs by open diamonds. Meta-analysis is performed by ﬁxed
effects model. Abbreviations as in Figure 2.
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2097prevention were characterized as having more than 1 major
risk factor (7,26,28,30), a single major risk factor as hyp-
ercholesterolemia (27,31), or elevated C-reactive protein
levels (29). Thus, our results apply to these categories of
elderly subjects and should not be generalized. Additional
risk factors (36–38), and in particular subclinical athero-
sclerosis measuring carotid intima-media thickness (39) or
coronary artery calcium scoring (40), may help selecting
elderly high-risk subjects in whom statin treatment may
reduce short-term CV risk, but this approach remains
unproven and deserves investigation (4).
The cost-beneﬁt evaluation of treatment in elderly people
must also be considered. From our analysis, 24 or 42 elderly
subjects without established CV disease would need to be
treated with statins for 1 year to prevent 1 MI or 1 stroke,
respectively. The cost of treatment should be weighed
against the costs of disability and caregiving for subjects
experiencing an MI or stroke, but these costs are highly
variable among different health systems. However, the cost-
beneﬁt assessment of statin treatment in elderly subjects
without CV disease must also take into account the reduced
beneﬁt of treatment associated with aging due to the
increased incidence of competing non-CV clinical events
that partially offsets the life expectancy gain provided by
treatment (41). Finally, as emphasized by guidelines (3,4),
medical (cognitive function, comorbidities) and social factors
speciﬁc to elderly individuals and impacting on adherence to
treatment must also be taken into account when considering
drug prescription in this age group.Study limitations. The current analysis was based on
aggregate and not on patient-level data. In addition, only
2 studies (7,27) included in the meta-analysis were designed
to enroll elderly patients, whereas the majority of patients
included represent elderly subgroups of clinical trials. Three
clinical trials (22–24) enrolling potentially eligible patients
could not be included in our study as we could not obtain
information from the authors. However, most of these
patients were enrolled in the Heart Protection Study (23)
that reported no difference in outcomes between younger
and elderly subjects as well as between subjects with and
without previous CV disease. Thus, although we could not
obtain data for the subgroup of elderly patients without CV
disease, it is unlikely that this would alter the results of our
analysis. Moreover, whether more intensive compared with
less intensive lipid lowering inﬂuences clinical outcomes in
elderly patients without CV disease could not be assessed in
the current analysis. We also could not separately assess
whether the beneﬁts of statins in elderly subjects without CV
disease differ between male and female subjects or in diabetic
versus nondiabetic patients, although previous meta-analyses
in subjects withoutCVdisease reported a signiﬁcant beneﬁt of
statin treatment in both sexes (35,42). Finally, the short-term
follow-up of trials included should also be acknowledged for
2 main aspects: 1) the potential impact on the nonsigniﬁcant
effect on mortality that might need longer observation to
reach statistical signiﬁcance; and 2) the evaluation of side
effects, and in particular of new cancer incidence, that needs
longer observation to be adequately assessed.
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2098Conclusions
In elderly subjects at high CV risk and without established
CV disease, statins substantially reduce the incidence of MI
and stroke in a short-term follow-up, with a favorable, albeit
nonsigniﬁcant, trend for reduction in mortality.
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